Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ECIS-European Cancer Information System. https://ecis.jrc.ec.europa.eu (25 March 2019, date last accessed).

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492

McTiernan, 2003, Behavioral risk factors in breast cancer: can risk be modified?, Oncologist, 8, 326, 10.1634/theoncologist.8-4-326

Autier, 2010, Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database, BMJ, 341, c3620., 10.1136/bmj.c3620

Allemani, 2015, Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet, 385, 977, 10.1016/S0140-6736(14)62038-9

Ottini, 2010, Male breast cancer, Crit Rev Oncol Hematol, 73, 141, 10.1016/j.critrevonc.2009.04.003

Report on the implementation of the Council Recommendation on Cancer Screening in the European Union. https://ecis.jrc.ec.europa.eu (25 March 2019, date last accessed).

Perry, 2007, European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition—summary document, Ann Oncol, 19, 614, 10.1093/annonc/mdm481

European guidelines for breast cancer screening and diagnosis. https://publications.europa.eu/s/jPcX (25 March 2015, 2019, date last accessed).

Gotzsche, 2011, Screening for breast cancer with mammography, Cochrane Database Syst Rev, 1, CD001877

Lauby-Secretan, 2015, Breast-cancer screening–viewpoint of the IARC Working Group, N Engl J Med, 372, 2353, 10.1056/NEJMsr1504363

Independent, 2012, The benefits and harms of breast cancer screening: an independent review, Lancet, 380, 1778, 10.1016/S0140-6736(12)61611-0

Warner, 2008, Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer, Ann Intern Med, 148, 671, 10.7326/0003-4819-148-9-200805060-00007

Sardanelli, 2010, Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group, Eur J Cancer, 46, 1296, 10.1016/j.ejca.2010.02.015

Lakhani, 2012, 4

Giuliano, 2017, Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 290, 10.3322/caac.21393

Hammond, 2011, ASCO-CAP guidelines for breast predictive factor testing: an update, Appl Immunohistochem Mol Morphol, 19, 499, 10.1097/PAI.0b013e31822a8eac

Wolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update, J Clin Oncol, 36, 2105, 10.1200/JCO.2018.77.8738

Duffy, 2017, Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM), Eur J Cancer, 75, 284, 10.1016/j.ejca.2017.01.017

Penault-Llorca, 2017, Ki67 assessment in breast cancer: an update, Pathology, 49, 166, 10.1016/j.pathol.2016.11.006

Mann, 2005, Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer, J Clin Oncol, 23, 5148, 10.1200/JCO.2005.02.076

Chen, 2012, Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis, Breast Cancer Res Treat, 134, 957, 10.1007/s10549-012-1990-z

Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303

Dai, 2015, Breast cancer intrinsic subtype classification, clinical use and future trends, Am J Cancer Res, 5, 2929

Dieci, 2018, Semin Cancer Biol, 52, 16, 10.1016/j.semcancer.2017.10.003

Wein, 2017, Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions, Front Oncol, 7, 156., 10.3389/fonc.2017.00156

Loi, 2019, Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers, J Clin Oncol, 37, 559, 10.1200/JCO.18.01010

National Comprehensive Cancer Network guidelines for treatment of breast cancer. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (12 February 2019, date last accessed).

Paluch-Shimon, 2016, Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening, Ann Oncol, 27, v103, 10.1093/annonc/mdw327

Krop, 2017, Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update, J Clin Oncol, 35, 2838, 10.1200/JCO.2017.74.0472

Koolen, 2012, 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques, Breast Cancer Res Treat, 131, 117, 10.1007/s10549-011-1767-9

Robertson, 2011, FDG-PET/CT in the staging of local/regional metastases in breast cancer, Breast, 20, 491, 10.1016/j.breast.2011.07.002

Blamey, 2007, Reading the prognosis of the individual with breast cancer, Eur J Cancer, 43, 1545, 10.1016/j.ejca.2007.01.003

Ravdin, 2001, Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer, J Clin Oncol, 19, 980, 10.1200/JCO.2001.19.4.980

Wishart, 2011, A population-based validation of the prognostic model PREDICT for early breast cancer, Eur J Surg Oncol, 37, 411, 10.1016/j.ejso.2011.02.001

Harbeck, 2014, Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow, Cancer Treat Rev, 40, 434, 10.1016/j.ctrv.2013.09.014

Cardoso, 2016, 70-gene signature as an aid to treatment decisions in early-stage breast cancer, N Engl J Med, 375, 717, 10.1056/NEJMoa1602253

Nitz, 2017, Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, Breast Cancer Res Treat, 165, 573, 10.1007/s10549-017-4358-6

Sparano, 2018, Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, 379, 111, 10.1056/NEJMoa1804710

Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 101, 1446, 10.1093/jnci/djp335

Wazir, 2014, Emerging gene-based prognostic tools in early breast cancer: first steps to personalised medicine, World J Clin Oncol, 5, 795, 10.5306/wjco.v5.i5.795

Drukker, 2013, A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study, Int J Cancer, 133, 929, 10.1002/ijc.28082

Hall, 2017, Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial, Value Health, 20, 1311, 10.1016/j.jval.2017.04.021

Petkov, 2016, Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study, NPJ Breast Cancer, 2, 16017., 10.1038/npjbcancer.2016.17

Esserman, 2017, Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades, JAMA Oncol, 3, 1503, 10.1001/jamaoncol.2017.1261

Harris, 2016, Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline summary, J Oncol Pract, 12, 384, 10.1200/JOP.2016.010868

Bossuyt, 2015, Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann Oncol, 26, 1280, 10.1093/annonc/mdv161

Cortazar, 2014, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 164, 10.1016/S0140-6736(13)62422-8

Symmans, 2007, Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol, 25, 4414, 10.1200/JCO.2007.10.6823

Cardoso, 2017, European Breast Cancer Conference manifesto on breast centres/units, Eur J Cancer, 72, 244, 10.1016/j.ejca.2016.10.023

Wilson, 2013, The requirements of a specialist breast centre, Eur J Cancer, 49, 3579, 10.1016/j.ejca.2013.07.017

Senkus, 2014, Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies, Psychooncology, 23, 173, 10.1002/pon.3384

Lee, 2006, American Society of Clinical Oncology recommendations on fertility preservation in cancer patients, J Clin Oncol, 24, 2917, 10.1200/JCO.2006.06.5888

Paluch-Shimon, 2017, ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3), Breast, 35, 203, 10.1016/j.breast.2017.07.017

Cardoso, 2012, The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur, J Cancer, 48, 3355

Peccatori, 2013, Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi160, 10.1093/annonc/mdt199

2009, Surgical guidelines for the management of breast cancer, Eur J Surg Oncol, 35, 1

Albornoz, 2015, Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction, Plast Reconstr Surg, 135, 1518, 10.1097/PRS.0000000000001276

Hwang, 2013, Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status, Cancer, 119, 1402, 10.1002/cncr.27795

van Maaren, 2016, 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study, Lancet Oncol, 17, 1158, 10.1016/S1470-2045(16)30067-5

Lagendijk, 2018, Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients, Int J Cancer, 142, 165, 10.1002/ijc.31034

Gentilini, 2017, Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients, Breast, 35, 32, 10.1016/j.breast.2017.06.004

Schnitt, 2015, The Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer: perspectives for pathologists, Arch Pathol Lab Med, 139, 575, 10.5858/arpa.2014-0384-ED

Morrow, 2016, Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ, J Clin Oncol, 34, 4040, 10.1200/JCO.2016.68.3573

Houssami, 2010, Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy, Eur J Cancer, 46, 3219, 10.1016/j.ejca.2010.07.043

Moran, 2014, Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 32, 1507, 10.1200/JCO.2013.53.3935

De La Cruz, 2015, Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review, Ann Surg Oncol, 22, 3241, 10.1245/s10434-015-4739-1

Wei, 2016, Psychosocial and sexual well-being following nipple-sparing mastectomy and reconstruction, Breast J, 22, 10, 10.1111/tbj.12542

Chatterjee, 2009, Effect of postoperative radiotherapy on autologous deep inferior epigastric perforator flap volume after immediate breast reconstruction, Br J Surg, 96, 1135, 10.1002/bjs.6693

Senkus-Konefka, 2004, Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation, Cancer Treat Rev, 30, 671, 10.1016/j.ctrv.2004.06.008

Cardoso, 2019, EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants, Breast, 44, 90, 10.1016/j.breast.2019.01.011

Donker, 2014, Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 15, 1303, 10.1016/S1470-2045(14)70460-7

Gebruers, 2015, Incidence and time path of lymphedema in sentinel node negative breast cancer patients: a systematic review, Arch Phys Med Rehabil, 96, 1131, 10.1016/j.apmr.2015.01.014

Krag, 2010, Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 11, 927, 10.1016/S1470-2045(10)70207-2

Giuliano, 2011, Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer, JAMA, 306, 385, 10.1001/jama.2011.1034

Lyman, 2017, Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 35, 561, 10.1200/JCO.2016.71.0947

National Comprehensive Cancer Network guidelines for treatment of breast cancer. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (25 March, 2019, date last accessed).

Weaver, 2010, Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale, Mod Pathol, 23, S26, 10.1038/modpathol.2010.36

Galimberti, 2013, Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial, Lancet Oncol, 14, 297, 10.1016/S1470-2045(13)70035-4

Giuliano, 2017, Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial, JAMA, 318, 918, 10.1001/jama.2017.11470

Jagsi, 2014, Radiation field design in the ACOSOG Z0011 (Alliance) Trial, J Clin Oncol, 32, 3600, 10.1200/JCO.2014.56.5838

Leidenius, 2006, Tumour-positive sentinel node findings in patients with ductal carcinoma in situ, J Surg Oncol, 94, 380, 10.1002/jso.20581

Moore, 2007, Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit, Ann Surg Oncol, 14, 2911, 10.1245/s10434-007-9414-8

Meijnen, 2007, Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy, Br J Surg, 94, 952, 10.1002/bjs.5735

Yen, 2005, Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ, J Am Coll Surg, 200, 516, 10.1016/j.jamcollsurg.2004.11.012

Hessler, 2017, Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database, Ann Surg Oncol, 24, 2907, 10.1245/s10434-017-5928-x

Wu, 2017, Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: a population-based analysis, J Cancer, 8, 3849, 10.7150/jca.21217

Kuchenbaecker, 2017, Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, JAMA, 317, 2402, 10.1001/jama.2017.7112

Ludwig, 2016, Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review, Am J Surg, 212, 660, 10.1016/j.amjsurg.2016.06.010

Heemskerk-Gerritsen, 2015, Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis, Int J Cancer, 136, 668, 10.1002/ijc.29032

El Hage Chehade, 2016, Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients, Am J Surg, 212, 969, 10.1016/j.amjsurg.2016.07.018

Galimberti, 2016, Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment, Eur J Surg Oncol, 42, 361, 10.1016/j.ejso.2015.11.019

Kuehn, 2013, Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study, Lancet Oncol, 14, 609, 10.1016/S1470-2045(13)70166-9

Boughey, 2013, Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial, JAMA, 310, 1455, 10.1001/jama.2013.278932

Donker, 2015, Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure, Ann Surg, 261, 378, 10.1097/SLA.0000000000000558

Caudle, 2016, Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection, J Clin Oncol, 34, 1072, 10.1200/JCO.2015.64.0094

Siso, 2018, Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment, Ann Surg Oncol, 25, 784, 10.1245/s10434-017-6270-z

Darby, 2011, Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials, Lancet, 378, 1707, 10.1016/S0140-6736(11)61629-2

van Werkhoven, 2011, Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial, Radiother Oncol, 100, 101, 10.1016/j.radonc.2011.07.004

Bartelink, 2015, Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial, Lancet Oncol, 16, 47, 10.1016/S1470-2045(14)71156-8

Coles, 2017, Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial, Lancet, 390, 1048, 10.1016/S0140-6736(17)31145-5

Livi, 2015, Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial, Eur J Cancer, 51, 451, 10.1016/j.ejca.2014.12.013

Polgár, 2017, Lancet Oncol, 18, 259, 10.1016/S1470-2045(17)30011-6

Veronesi, 2013, Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial, Lancet Oncol, 14, 1269, 10.1016/S1470-2045(13)70497-2

Vaidya, 2014, Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 383, 603, 10.1016/S0140-6736(13)61950-9

Polgár, 2010, Radiother Oncol, 94, 264, 10.1016/j.radonc.2010.01.014

McGale, 2014, Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials, Lancet, 383, 2127, 10.1016/S0140-6736(14)60488-8

Poortmans, 2015, Internal mammary and medial supraclavicular irradiation in breast cancer, N Engl J Med, 373, 317, 10.1056/NEJMoa1415369

Whelan, 2015, Regional nodal irradiation in early-stage breast cancer, N Engl J Med, 373, 1878, 10.1056/NEJMoa1415340

Thorsen, 2016, DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer, J Clin Oncol, 34, 314, 10.1200/JCO.2015.63.6456

Poortmans, 2014, Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate, Lancet, 383, 2104, 10.1016/S0140-6736(14)60192-6

Offersen, 2015, ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, Radiother Oncol, 114, 3, 10.1016/j.radonc.2014.11.030

Spear, 2008, Options in reconstructing the irradiated breast, Plast Reconstr Surg, 122, 379, 10.1097/PRS.0b013e31817d605f

Momoh, 2014, A systematic review of complications of implant-based breast reconstruction with prereconstruction and postreconstruction radiotherapy, Ann Surg Oncol, 21, 118, 10.1245/s10434-013-3284-z

Kelley, 2014, A systematic review of morbidity associated with autologous breast reconstruction before and after exposure to radiotherapy: are current practices ideal?, Ann Surg Oncol, 21, 1732, 10.1245/s10434-014-3494-z

Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, N Engl J Med, 362, 513, 10.1056/NEJMoa0906260

Bentzen, 2008, The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet, 371, 1098, 10.1016/S0140-6736(08)60348-7

Bentzen, 2008, The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet Oncol, 9, 331, 10.1016/S1470-2045(08)70077-9

Goodwin, 2009, Post-operative radiotherapy for ductal carcinoma in situ of the breast–a systematic review of the randomised trials, Breast, 18, 143, 10.1016/j.breast.2009.04.003

Morrow, 2015, Current management of lesions associated with an increased risk of breast cancer, Nat Rev Clin Oncol, 12, 227, 10.1038/nrclinonc.2015.8

Barbour, 2017, Patterns of care for ductal carcinoma in situ of the breast: Queensland's experience over a decade, Breast, 35, 169, 10.1016/j.breast.2017.07.003

Rakovitch, 2018, Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy, Breast, 37, 181, 10.1016/j.breast.2017.07.002

Correa, 2017, Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement, Pract Radiat Oncol, 7, 73, 10.1016/j.prro.2016.09.007

Lohrisch, 2006, Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer, J Clin Oncol, 24, 4888, 10.1200/JCO.2005.01.6089

Harbeck, 2002, Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424), Cancer Res, 62, 4617

Curigliano, 2017, De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017, Ann Oncol, 28, 1700, 10.1093/annonc/mdx308

Wei, 2016, Papillary lesions of the breast: an update, Arch Pathol Lab Med, 140, 628, 10.5858/arpa.2015-0092-RA

Albain, 2009, Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial, Lancet, 374, 2055, 10.1016/S0140-6736(09)61523-3

2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0

Goss, 2003, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 349, 1793, 10.1056/NEJMoa032312

Swain, 2010, Amenorrhea from breast cancer therapy–not a matter of dose, N Engl J Med, 363, 2268, 10.1056/NEJMc1009616

Pagani, 1998, Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI, Eur J Cancer, 34, 632, 10.1016/S0959-8049(97)10036-3

Francis, 2015, Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med, 372, 436, 10.1056/NEJMoa1412379

Francis, 2018, Tailoring adjuvant endocrine therapy for premenopausal breast cancer, N Engl J Med, 379, 122, 10.1056/NEJMoa1803164

Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285

Pagani, 2014, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 371, 107, 10.1056/NEJMoa1404037

Moore, 2015, Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy, N Engl J Med, 372, 923, 10.1056/NEJMoa1413204

Lambertini, 2018, Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data, J Clin Oncol, 36, 1981, 10.1200/JCO.2018.78.0858

Bliss, 2012, Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study, J Clin Oncol, 30, 709, 10.1200/JCO.2010.33.7899

Regan, 2011, Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncol, 12, 1101, 10.1016/S1470-2045(11)70270-4

Cuzick, 2010, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol, 11, 1135, 10.1016/S1470-2045(10)70257-6

Goss, 2008, Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen, J Clin Oncol, 26, 1948, 10.1200/JCO.2007.11.6798

Burstein, 2010, American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, J Clin Oncol, 28, 3784, 10.1200/JCO.2009.26.3756

Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J Clin Oncol, 28, 509, 10.1200/JCO.2009.23.1274

Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1

Leyland-Jones, 2011, Abstract S1-8: outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG trial, Cancer Res, 70, S1

Sideras, 2010, Coprescription of tamoxifen and medications that inhibit CYP2D6, J Clin Oncol, 28, 2768, 10.1200/JCO.2009.23.8931

Berry, 2006, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, 295, 1658, 10.1001/jama.295.14.1658

Clarke, 2008, Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials, Lancet, 371, 29, 10.1016/S0140-6736(08)60069-0

Peto, 2012, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 379, 432, 10.1016/S0140-6736(11)61625-5

Samuel, 2015, Abstract S3-02: nSABP B-36: a randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer, Cancer Res, 75

Nitz, 2017, Final analysis of the prospective WSG-AGO EC-doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression, Ann Oncol, 28, 2899., 10.1093/annonc/mdw349

Gianni, 2009, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, 27, 2474, 10.1200/JCO.2008.19.2567

Shao, 2012, Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials, Breast, 21, 389, 10.1016/j.breast.2012.03.011

Earl, 2014, Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial, Lancet Oncol, 15, 201, 10.1016/S1470-2045(13)70554-0

Jones, 2009, Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735, J Clin Oncol, 27, 1177, 10.1200/JCO.2008.18.4028

Blum, 2017, Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology), J Clin Oncol, 35, 2647, 10.1200/JCO.2016.71.4147

Sousa, 2015, Central venous access in oncology: ESMO Clinical Practice Guidelines, Ann Oncol, 26, v152, 10.1093/annonc/mdv296

Citron, 2003, J Clin Oncol, 21, 1431, 10.1200/JCO.2003.09.081

Gray, 2018, Cancer Res, 78, GS1

Cameron, 2017, 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial, Lancet, 389, 1195, 10.1016/S0140-6736(16)32616-2

Perez, 2014, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol, 32, 3744, 10.1200/JCO.2014.55.5730

Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383

Gonzalez-Angulo, 2009, High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller, J Clin Oncol, 27, 5700, 10.1200/JCO.2009.23.2025

Joensuu, 2009, Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial, J Clin Oncol, 27, 5685, 10.1200/JCO.2008.21.4577

Goldhirsch, 2013, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet, 382, 1021, 10.1016/S0140-6736(13)61094-6

Pivot, 2013, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol, 14, 741, 10.1016/S1470-2045(13)70225-0

Joensuu, 2018, Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial, JAMA Oncol, 4, 1199, 10.1001/jamaoncol.2018.1380

Conte, 2017, 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian study Short-HER, J Clin Oncol, 35, 501, 10.1200/JCO.2017.35.15_suppl.501

Earl, 2018, PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results, J Clin Oncol, 36, 506, 10.1200/JCO.2018.36.15_suppl.506

Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3

Guarneri, 2012, Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study, J Clin Oncol, 30, 1989, 10.1200/JCO.2011.39.0823

Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9

Piccart-Gebhart, 2016, Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial, J Clin Oncol, 34, 1034, 10.1200/JCO.2015.62.1797

von Minckwitz, 2017, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, N Engl J Med, 377, 122, 10.1056/NEJMoa1703643

von Minckwitz, 2019, Trastuzumab emtansine for residual invasive HER2-positive breast cancer, N Engl J Med, 380, 617, 10.1056/NEJMoa1814017

Martin, 2017, Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1688, 10.1016/S1470-2045(17)30717-9

Tolaney, 2015, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 372, 134, 10.1056/NEJMoa1406281

Rastogi, 2008, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, 26, 778, 10.1200/JCO.2007.15.0235

von Minckwitz, 2014, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, 15, 747, 10.1016/S1470-2045(14)70160-3

Sikov, 2015, J Clin Oncol, 33, 13, 10.1200/JCO.2014.57.0572

Loibl, 2018, Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial, Lancet Oncol, 19, 497, 10.1016/S1470-2045(18)30111-6

Hahnen, 2017, Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial, JAMA Oncol, 3, 1378, 10.1001/jamaoncol.2017.1007

Masuda, 2017, Adjuvant capecitabine for breast cancer after preoperative chemotherapy, N Engl J Med, 376, 2147, 10.1056/NEJMoa1612645

von Minckwitz, 2011, Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 125, 145, 10.1007/s10549-010-1228-x

Cataliotti, 2006, Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial, Cancer, 106, 2095, 10.1002/cncr.21872

Smith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol, 23, 5108, 10.1200/JCO.2005.04.005

Eiermann, 2001, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study, Ann Oncol, 12, 1527, 10.1023/A:1013128213451

Eggemann, 2013, Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients, Breast Cancer Res Treat, 137, 465, 10.1007/s10549-012-2355-3

Korde, 2010, Multidisciplinary meeting on male breast cancer: summary and research recommendations, J Clin Oncol, 28, 2114, 10.1200/JCO.2009.25.5729

Sousa, 2013, An update on male breast cancer and future directions for research and treatment, Eur J Pharmacol, 717, 71, 10.1016/j.ejphar.2013.03.037

Cardoso, 2018, Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program, Ann Oncol, 29, 405, 10.1093/annonc/mdx651

Azim, 2013, Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement, Ann Oncol, 24, 647, 10.1093/annonc/mds645

Masuda, 2012, Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial, Lancet Oncol, 13, 345, 10.1016/S1470-2045(11)70373-4

Coleman, 2014, Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial, Lancet Oncol, 15, 997, 10.1016/S1470-2045(14)70302-X

2015, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, 386, 1353, 10.1016/S0140-6736(15)60908-4

Dhesy-Thind, 2017, Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 35, 2062, 10.1200/JCO.2016.70.7257

Eidtmann, 2010, Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study, Ann Oncol, 21, 2188, 10.1093/annonc/mdq217

Hadji, 2017, Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG, J Bone Oncol, 7, 1, 10.1016/j.jbo.2017.03.001

Muss, 2009, Adjuvant chemotherapy in older women with early-stage breast cancer, N Engl J Med, 360, 2055, 10.1056/NEJMoa0810266

Perrone, 2015, Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial, Ann Oncol, 26, 675, 10.1093/annonc/mdu564

Crivellari, 2013, Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: the CASA randomized trial, Breast, 22, 130, 10.1016/j.breast.2013.01.015

Biganzoli, 2012, Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), Lancet Oncol, 13, e148, 10.1016/S1470-2045(11)70383-7

Staley, 2012, Postoperative tamoxifen for ductal carcinoma in situ, Cochrane Database Syst Rev, 10, CD007847

Forbes, 2016, Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, Lancet, 387, 866, 10.1016/S0140-6736(15)01129-0

Margolese, 2016, Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial, Lancet, 387, 849, 10.1016/S0140-6736(15)01168-X

Allemani, 2013, Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002, Int J Cancer, 132, 2404, 10.1002/ijc.27895

Pan, 2017, 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years, N Engl J Med, 377, 1836, 10.1056/NEJMoa1701830

Park, 2012, Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry, Breast, 21, 50, 10.1016/j.breast.2011.07.008

2014, Committee Opinion No. 601: tamoxifen and uterine cancer, Obstet Gynecol, 123, 1394, 10.1097/01.AOG.0000450757.18294.cf

Mustian, 2017, Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis, JAMA Oncol, 3, 961, 10.1001/jamaoncol.2016.6914

Chlebowski, 2002, Weight loss in breast cancer patient management, J Clin Oncol, 20, 1128, 10.1200/JCO.2002.20.4.1128

Holmberg, 2008, Increased risk of recurrence after hormone replacement therapy in breast cancer survivors, J Natl Cancer Inst, 100, 475, 10.1093/jnci/djn058

Cherny, 2017, ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, 28, 2340, 10.1093/annonc/mdx310

Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393

Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805